Physician profile
Gregg Shepard
NPI 1023205531
$14,562.25
in general payments reported to CMS, 2019-2025
73 companies · $4,275 in 2025
The $4,275 reported for 2025 was more than what 80% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,279 · 2020: $559 · 2021: $11.92 · 2022: $774 · 2023: $2,204 · 2024: $2,460 · 2025: $4,275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,939.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,938.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $1,593.97 | 2019-2025 | Reblozyl, Pomalyst |
| Merck Sharp & Dohme LLC | $1,134.09 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $920.10 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $877.30 | 2019-2025 | Calquence, Tagrisso, Lynparza |
| Janssen Biotech, INC. | $604.43 | 2019-2025 | Darzalex, Rybrevant, Imbruvica |
| Genzyme Corporation | $487.71 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $462.27 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Novocure INC. | $418.49 | 2019-2025 | Optune Lua (Novottf-200t), Optune Gio |
| Pfizer INC. | $416.20 | 2019-2025 | |
| Amgen INC. | $382.24 | 2019-2023 | Kyprolis |
| Bayer Healthcare Pharmaceuticals INC. | $379.13 | 2019-2025 | |
| Incyte Corporation | $341.71 | 2019-2025 | Monjuvi, Jakafi, Zynyz |
| Eisai INC. | $339.46 | 2019-2025 | |
| Genentech USA, INC. | $310.81 | 2019-2025 | Tecentriq, Polivy, Venclexta |
| Medtronic, INC. | $295.25 | 2022 |
Show all 72 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $289.80 | 2022-2025 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $270.05 | 2019-2025 | Iclusig, Alunbrig, Ninlaro |
| Astellas Pharma US INC | $269.61 | 2019-2025 | Vyloy, Padcev, Xtandi |
| Abbvie INC. | $252.43 | 2020-2025 | Venclexta |
| Lilly USA, LLC | $240.76 | 2019-2025 | Verzenio, Retevmo, Jaypirca |
| Gilead Sciences, INC. | $237.15 | 2019-2025 | Trodelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.01 | 2025 | |
| Stemline Therapeutics INC. | $195.70 | 2023-2025 | Orserdu |
| Aveo Pharmaceuticals, INC. | $191.54 | 2023-2025 | Fotivda |
| Regeneron Healthcare Solutions, INC. | $185.42 | 2022-2025 | Libtayo |
| Emd Serono, INC. | $170.98 | 2019-2025 | Bavencio |
| Exelixis INC. | $166.26 | 2019-2025 | Cabometyx |
| Alexion Pharmaceuticals, INC. | $163.02 | 2019-2025 | Ultomiris |
| Kite Pharma, INC. | $160.17 | 2020-2025 | Yescarta |
| Tesaro, INC. | $158.89 | 2019 | |
| Adc Therapeutics America, INC. | $158.04 | 2023-2025 | |
| Pharmaessentia USA Corporation | $139.88 | 2023-2025 | Besremi |
| Rigel Pharmaceuticals, INC. | $136.75 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Puma Biotechnology, INC. | $133.28 | 2019-2025 | |
| Seagen INC. | $128.69 | 2019-2023 | Tukysa, Padcev |
| Tersera Therapeutics LLC | $117.81 | 2022-2025 | Zoladex, Xermelo |
| Adaptive Biotechnologies Corporation | $114.93 | 2022 | |
| Jazz Pharmaceuticals INC. | $103.67 | 2023 | |
| Genmab U.S., INC. | $102.79 | 2024-2025 | Epkinly |
| Pharmacyclics LLC, An Abbvie Company | $95.48 | 2019-2023 | Imbruvica |
| Servier Pharmaceuticals LLC | $92.47 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $83.85 | 2023-2025 | Orgovyx |
| Sun Pharmaceutical Industries INC. | $76.22 | 2024-2025 | |
| Blueprint Medicines Corporation | $74.15 | 2024-2025 | Ayvakit |
| Deciphera Pharmaceuticals INC. | $68.30 | 2024-2025 | Qinlock, Romvimza |
| Beigene USA, INC. | $62.55 | 2023-2024 | Brukinsa |
| Pharmacosmos Therapeutics INC. | $59.58 | 2024 | Cosela, Monoferric |
| Glaxosmithkline, LLC. | $58.83 | 2020-2024 | Ojjaara |
| Iovance Biotherapeutics, INC. | $45.97 | 2025 | Amtagvi |
| Teva Pharmaceuticals USA, INC. | $45.93 | 2019 | |
| Karyopharm Therapeutics INC. | $41.02 | 2025 | Xpovio |
| Taiho Oncology, INC. | $40.66 | 2024 | |
| Mirati Therapeutics, INC. | $38.69 | 2023-2024 | Krazati |
| Legend Biotech USA INC. | $36.88 | 2025 | Carvykti |
| Cti Biopharma Corp. | $35.60 | 2023 | Vonjo |
| Sobi, INC | $35.47 | 2025 | |
| Beone Medicines USA, INC. | $29.82 | 2025 | Tevimbra |
| Tempus Ai, INC | $27.34 | 2025 | Xt Cdx |
| Aurobindo Pharma USA, INC. | $25.92 | 2019 | |
| Clovis Oncology, INC. | $23.42 | 2019 | |
| Coherus Oncology, INC. | $21.52 | 2024 | |
| Macrogenics, INC. | $20.54 | 2023 | |
| Morphosys, US INC. | $18.49 | 2023 | Monjuvi |
| Ipsen Biopharmaceuticals, INC | $18.11 | 2019 | |
| G1 Therapeutics, INC. | $18.09 | 2022 | |
| Array Biopharma INC | $17.43 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $17.05 | 2019 | |
| Boston Scientific Corporation | $16.18 | 2025 | Wavewriter Alpha Prime 16 |
| Eusa Pharma (US) LLC | $14.59 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.59 | 2019 | |
| Dova Pharmaceuticals | $11.82 | 2019 | |
| Verastem, INC. | $10.90 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregg Shepard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.